PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL

The TRACER trial compared vorapaxar, a novel oral PAR-1 antagonist, with placebo, as add-on therapy to standard of care, among 12944 NSTE ACS patients who were predominantly treated with aspirin and clopidogrel. While vorapaxar was associated with a significant increase in major bleeding in the